BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 32998746)

  • 1. Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure.
    Sayour AA; Oláh A; Ruppert M; Barta BA; Horváth EM; Benke K; Pólos M; Hartyánszky I; Merkely B; Radovits T
    Cardiovasc Diabetol; 2020 Sep; 19(1):159. PubMed ID: 32998746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure.
    Sayour AA; Ruppert M; Oláh A; Benke K; Barta BA; Zsáry E; Ke H; Horváth EM; Merkely B; Radovits T
    Antioxidants (Basel); 2021 Jul; 10(8):. PubMed ID: 34439438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
    Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
    Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
    Banerjee SK; McGaffin KR; Pastor-Soler NM; Ahmad F
    Cardiovasc Res; 2009 Oct; 84(1):111-8. PubMed ID: 19509029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1.
    Sayour AA; Ruppert M; Oláh A; Benke K; Barta BA; Zsáry E; Merkely B; Radovits T
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cardiac resynchronization therapy on left ventricular remodeling and dyssynchrony in patients with left ventricular noncompaction and heart failure.
    Qiu Q; Chen YX; Mai JT; Yuan WL; Wei YL; Liu YM; Yang L; Wang JF
    Int J Cardiovasc Imaging; 2015 Feb; 31(2):329-37. PubMed ID: 25392055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Roles of Sodium-Glucose Cotransporter 1 (SGLT1) in the Induction of Cardiac Remodeling].
    Hirose M; Matsushita N; Ishida N; Ibi M; Saito M
    Yakugaku Zasshi; 2018; 138(7):939-943. PubMed ID: 29962473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.
    Di Franco A; Cantini G; Tani A; Coppini R; Zecchi-Orlandini S; Raimondi L; Luconi M; Mannucci E
    Int J Cardiol; 2017 Sep; 243():86-90. PubMed ID: 28526540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.
    Ramratnam M; Sharma RK; D'Auria S; Lee SJ; Wang D; Huang XY; Ahmad F
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25092788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction.
    Amorim S; Rodrigues J; Campelo M; Moura B; Martins E; Macedo F; Silva-Cardoso J; Maciel MJ
    Int J Cardiovasc Imaging; 2017 May; 33(5):605-613. PubMed ID: 28013418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders.
    Vanderheyden M; Mullens W; Delrue L; Goethals M; de Bruyne B; Wijns W; Geelen P; Verstreken S; Wellens F; Bartunek J
    J Am Coll Cardiol; 2008 Jan; 51(2):129-36. PubMed ID: 18191736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes.
    Bolla AM; Butera E; Pellegrini S; Caretto A; Bonfanti R; Zuppardo RA; Barera G; Cavestro GM; Sordi V; Bosi E
    Acta Diabetol; 2020 Nov; 57(11):1367-1373. PubMed ID: 32617672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
    Linde C; Abraham WT; Gold MR; St John Sutton M; Ghio S; Daubert C;
    J Am Coll Cardiol; 2008 Dec; 52(23):1834-1843. PubMed ID: 19038680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts.
    Meng L; Uzui H; Guo H; Tada H
    Mol Med Rep; 2018 May; 17(5):6887-6892. PubMed ID: 29512713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.